This summer Nestlé Health Science sold Prometheus Laboratories, a gastrointestinal disease diagnostics unit it had acquired eight years prior, to a low-profile San Diego biotech called Precision IBD.

About a month ago, Precision—a drug and diagnostic developer that’s focused, as its name suggests, on inflammatory bowel disease (IBD)—changed its name to Prometheus Biosciences and tapped a former Salix Pharmaceuticals executive as its new CEO. Top executive Mark McKenna spent about four years at Salix, a GI-focused specialty pharmaceutical company owned by Bausch Health (NYSE: BHC), formerly known as Valeant Pharmaceuticals.

Now the San Diego company has a deal with… Read more »